Navigation Links
Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007/ITI-722
Date:4/9/2008

NEW YORK, April 9, 2008 /PRNewswire/ -- Intra-Cellular Therapies, Inc., today announced additional preclinical data from its ongoing development programs for ITI-007, the Company's first-in-class dual 5HT2A receptor antagonist/dopamine receptor phosphoprotein modulator (DPPM), and ITI-722, a low-dose formulation of ITI-007, which are in development for schizophrenia and sleep disorders, respectively. These new data demonstrate ITI-007 has preclinical activity both in vitro and in vivo as an antidepressant.

ITI-007 acts as a potent inhibitor of the serotonin transporter (SERT), a major target for most antidepressant drugs. To examine whether this in vitro activity could be predictive of behavioral activity in vivo, the antidepressant effect of ITI-007 was investigated using an animal model of depression involving social stress. Repeated treatment of ITI-007 improved performance in this animal model, consistent with antidepressant-like efficacy. The combined actions of ITI-007 as a SERT inhibitor, a 5HT2A receptor antagonist, and a DPPM may provide a unique, antidepressant drug with a more optimal profile, including a lack of sexual side effects common to other antidepressant drugs.

"These studies demonstrate ITI-007 may have antidepressant activity in addition to its potential in treating sleep maintenance insomnia and psychosis in patients," stated Sharon Mates, Ph.D., Chairman and Chief Executive Officer of Intra-Cellular Therapies. "We believe ITI-007 represents a unique compound that may have broad use in treating many neuropsychiatric and neurodegenerative disorders where sleep problems, depression, or psychosis are prominent symptoms, including schizophrenia, affective disorders, and Parkinson's disease."

About ITI-007

ITI-007 is an orally available compound which combines potent 5HT2A receptor antagonism with cell-type-specific modulation of phosphoprotein pathways downstream of dopamine receptors. As a dopamine receptor phos
'/>"/>

SOURCE Intra-Cellular Therapies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Intra-Cellular Therapies Presents Data on Its Schizophrenia and Cognition in Schizophrenia Programs at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders
2. Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia
3. Intra-Cellular Therapies Presents Preclinical Data From Schizophrenia and Sleep Maintenance Programs
4. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
5. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
6. Vital Therapies Announces Presentation of ELAD(R) Artificial Liver Data at American Association for the Study of Liver Diseases 2007 Annual Meeting
7. Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies
8. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
9. New Data Show Doripenem as Effective as Commonly Used Therapies in Treating Hospital-Acquired Pneumonias
10. ActiveSight and CHDI Leverage Fragment-Based Lead Discovery for Huntington Disease Therapies
11. LigoCyte Pharmaceuticals Announces Collaboration With Biogen Idec to Develop Anti-CD103 Therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... Oct. 1, 2014  Express Scripts (NASDAQ: ... 2015 Express Scripts Medicare ® Prescription Drug Plans ... Walgreens (NYSE: WAG ) (NASDAQ: ... and clinical support  for their Medicare dollars. ... Value or Choice plans for ...
(Date:10/1/2014)... 1, 2014 Ardelyx, Inc. (NASDAQ: ... company focused on cardio-renal, gastrointestinal and metabolic ... 371 patient Phase 2b clinical trial evaluating ... syndrome (IBS-C).  Results from this study demonstrated ... IBS-C symptoms for tenapanor-treated patients compared to ...
(Date:9/30/2014)... , Sept. 30, 2014 /CNW/ - Protecting the health and safety ... Health Canada uses the appropriate powers and tools at its disposal ... safety and quality standards. To that end, Health ... stop the import into Canada of all ... . They are: , Apotex Pharmachem India Pvt ...
Breaking Medicine Technology:Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 2Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 3Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 4Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 2Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 3Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 4Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 5Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 6Statement by the Honourable Rona Ambrose on the import ban of drug products from three plants in India 2
... Pacific Bridge Medical will be attending the Medical ... 28-30, 2010, at the Donald E. Stephens Convention ... is part of a national conference series for ... affairs within the pharmaceutical and medical device manufacturing ...
... 23 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) ... M. Bate to its Board of Directors. "We ... to our Board of Directors.  With experience, vision and proven ... to take on this important role in the company," said ...
Cached Medicine Technology:Asian Medical Markets Expert to Attend the MD&M Midwest Conference 2BioMarin Appoints William Young and Kenneth Bate to Its Board of Directors 2BioMarin Appoints William Young and Kenneth Bate to Its Board of Directors 3
(Date:10/1/2014)... Familylifeinsurancequotes.org has released a new blog ... citizens. , Senior citizens can qualify for affordable ... to seniors who are over 50 years old. Some ... a medical examination. , Term life insurance with a ... can qualify. Having life insurance during retirement is important ...
(Date:10/1/2014)... CA (PRWEB) October 01, 2014 Bedros ... Fit Body Boot Camp fitness boot camps, he’s also ... personal training , with sold out business summits, a ... as marketing consultant to a recent Spike TV reality ... says that now is the time for personal trainers ...
(Date:10/1/2014)... Hillsboro, Oregon (PRWEB) October 01, 2014 ... curing solutions , continues to expand the business worldwide. ... engineering along with additional capacity for manufacturing efforts. The ... over the last five years and expects this growth ... UV LED curing technology gains worldwide adoption. , ...
(Date:10/1/2014)... MO (PRWEB) October 01, 2014 Join the ... Castlewood Eating Disorder Treatment Center’s first ever charity golf tournament ... for people with eating disorders who cannot afford treatment. The ... Golf Club in Eureka, Mo. , The day-long event ... noon. A reception and award dinner will begin at 5 ...
(Date:10/1/2014)... October 01, 2014 Between 23 million ... the U.S., according to figures from the National Institutes ... Association (AARDA), and many of them have something else ... having undiagnosed celiac disease. Gluten Free Therapeutics, makers ... of undiagnosed celiac disease by publishing a series of ...
Breaking Medicine News(10 mins):Health News:Affordable Term Life Insurance - Senior Citizens Can Qualify for Coverage! 2Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 2Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 3Health News:Phoseon Technology Continues to Drive Growth Worldwide 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 3Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 3
... Financial contracts to care for sick or aging relatives ... new interest as everyday Americans wrestle with the time and ... legal expert says. , Law professor Richard L. Kaplan says ... a groundswell, and most people still bristle at the notion ...
... 27 Warner Chilcott Limited (Nasdaq: WCRX ) ... has filed for standard review the new drug application (NDA) ... NDA for WC 3016 was submitted by its subsidiary, Warner ... Warner Chilcott , Warner Chilcott is a leading ...
... Today, the Children,s Health Fund (CHF) announced a ... support a new health care clinic in the South ... Starr International Foundation grant will support the clinic,s medical ... The homeless health care clinic is part of the ...
... Inc. (OTC Bulletin Board: NVLX), an emerging healthcare ... distribute Infinitink (the world,s first permanent tattoo ink ... Zealand. The distribution agreement grants Jayhur Enterprises (Sydney, ... market, distribute and sell ...
... Kandahar, Afghanistan could help surgeons prepare for civilian disasters, ... two tours at the hospital. Dr. Vivian McAlister ... the Schulich School of Medicine & Dentistry at The ... the London Health Sciences Centre. He spent two months ...
... can lead to healthier livesST. LOUIS, May 27 ... rollout a new consumer health tool that will complement ... customers. Nurse Response will offer the Healthwise Knowledgebase, an ... Response consumers to access over 7,000 health topics online. ...
Cached Medicine News:Health News:Contracts adding legal twist to family health care 2Health News:Contracts adding legal twist to family health care 3Health News:Warner Chilcott Announces FDA Acceptance of NDA Submission for Low Dose Oral Contraceptive 2Health News:Warner Chilcott Announces FDA Acceptance of NDA Submission for Low Dose Oral Contraceptive 3Health News:Children's Health Fund Receives $500,000 from the Starr International Foundation to Support South Bronx Homeless Health Care Clinic 2Health News:Nuvilex Signs Agreement with Jayhur Enterprises to Distribute Infinitink - the World's First Permanent, But Easier to Remove Tattoo Ink - in Australia and New Zealand 2Health News:Nuvilex Signs Agreement with Jayhur Enterprises to Distribute Infinitink - the World's First Permanent, But Easier to Remove Tattoo Ink - in Australia and New Zealand 3Health News:Sharing surgical lessons from the Canadian field hospital in Afghanistan 2
... Our popular Back-Aid Apron ... improved Universal Back-Saver Belt that ... take more weight off your ... shoulder strap redistribute weight from ...
Freedom of movement - plus full circle, maximum radiation protection. No other full circle radiation protection design approaches the level of comfort of the VestSkirt, which divides weight between t...
... Cryo System is the first in portability and performance. ... surgeons who need a flexible, portable system with the ... CTU attaches easily to an "E" size tank and ... cryo to where it is needed.,The CTU Travel Case ...
... System is an easy-to-use, workflow-based system designed to ... Inspirex consists of the SleepWorks software and either ... and durable systems can be used for a ... - including full EEG recording - and have ...
Medicine Products: